RYZUMVI Drug Patent Profile
Which patents cover Ryzumvi, and when can generic versions of Ryzumvi launch?
Ryzumvi is a drug marketed by Famygen Life Sci and is included in one NDA. There are thirteen patents protecting this drug and one Paragraph IV challenge.
The generic ingredient in RYZUMVI is phentolamine mesylate. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ryzumvi
A generic version of RYZUMVI was approved as phentolamine mesylate by HIKMA on March 11th, 1998.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for RYZUMVI?
- What are the global sales for RYZUMVI?
- What is Average Wholesale Price for RYZUMVI?
Summary for RYZUMVI
| US Patents: | 13 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 1,267 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RYZUMVI |
| What excipients (inactive ingredients) are in RYZUMVI? | RYZUMVI excipients list |
| DailyMed Link: | RYZUMVI at DailyMed |
Pharmacology for RYZUMVI
| Drug Class | alpha-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists |
Paragraph IV (Patent) Challenges for RYZUMVI
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| RYZUMVI | Ophthalmic Solution | phentolamine mesylate | 0.75% | 217064 | 1 | 2024-12-16 |
US Patents and Regulatory Information for RYZUMVI
RYZUMVI is protected by thirteen US patents and one FDA Regulatory Exclusivity.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | 12,201,616 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | 12,350,366 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | 12,734,126 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | 10,772,829 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | 11,844,858 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RYZUMVI
See the table below for patents covering RYZUMVI around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2014212274 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof | ⤷ Start Trial |
| Australia | 2018200566 | AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF | ⤷ Start Trial |
| Canada | 2899339 | SOLUTIONS OPHTALMIQUES AQUEUSES DE PHENTOLAMINE ET UTILISATIONS MEDICALES ASSOCIEES (AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF) | ⤷ Start Trial |
| Denmark | 2950648 | ⤷ Start Trial | |
| European Patent Office | 2950648 | SOLUTIONS OPHTALMIQUES AQUEUSES DE PHENTOLAMINE ET UTILISATIONS MÉDICALES ASSOCIÉES (AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF) | ⤷ Start Trial |
| Spain | 2762153 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch